Scancell Holdings Plc Board Change (4045X)
August 10 2018 - 1:00AM
UK Regulatory
TIDMSCLP
RNS Number : 4045X
Scancell Holdings Plc
10 August 2018
10 August 2018
Scancell Holdings Plc
("Scancell" or the "Company")
Board Change
Scancell Holdings Plc (AIM: SCLP) today announces that Kate
Cornish-Bowden will be stepping down as Non-Executive Director as
of 31 August 2018 after seven years on the Board of the
Company.
Dr John Chiplin, Chairman of Scancell, commented:
"Kate has made an important contribution in guiding Scancell
through its formative years during her time on the Board and in her
role as chairman of the Remuneration Committee. We would like to
thank her for her hard work and wish her all the best for the
future."
For Further Information:
Scancell Holdings Plc
Dr John Chiplin, Chairman +44 (0) 20 3727 1000
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited
(Nominated Adviser and Corporate
broker)
Freddy Crossley/Emma Earl +44 (0) 20 7886 2500
FTI Consulting
Mo Noonan/Simon Conway +44 (0) 20 3727 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
parts of the cellular immune system. They can be used as
monotherapy or in combination with checkpoint inhibitors. This
platform has the potential to enhance tumour destruction, prevent
disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the
treatment of melanoma. A phase 1/2 clinical trial has so far
successfully demonstrated survival data of more than five
years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours. Scancell has entered into a
clinical development partnership with Cancer Research UK for
SCIB2.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents. It stimulates the production of
killer CD4+ T cells which overcome the immune suppression induced
by tumours, allowing activated T cells to seek out and kill tumour
cells that would otherwise be hidden from the immune system.
Moditope(R) alone, or in combination with other agents, has the
potential to treat a wide variety of cancers.
-- Modi-1 is being developed for the treatment of triple
negative breast cancer, ovarian cancer and sarcomas.
For further details, please see our website:
www.scancell.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAFKLLBVVFBBBF
(END) Dow Jones Newswires
August 10, 2018 02:00 ET (06:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024